VDR binds β-catenin and blocks its proliferative effects in the intestinal epithelia; it also acts by activation of cystatin D or induction of the myc antagonist, i.e., the c-myc/MAD1/MXD1 network, to suppress c-myc function, as well as by repressing the long non-coding (lnc) RNA CCAT2 (colon cancer associated transcript 2) and promoting the degradation of the myc protein in cancer [183,184,185,186,187]. The gene discussed is VDR; the disease is cancer.